

# Practical Model Selection for Virtual Chemical Screening

Shengchao Liu<sup>1,7</sup>, Moayad Alnammi<sup>1,7</sup>, Spencer Ericksen<sup>2,3,8</sup>, Andrew Voter<sup>4</sup>, James Keck<sup>4</sup>, Michael Hoffmann<sup>2,5</sup>, Scott Wildman<sup>2</sup>, Anthony Gitter<sup>1,3,6,7,8</sup>

<sup>1</sup>Department of Computer Sciences; <sup>2</sup>Small Molecule Screening Facility; <sup>3</sup>Center for Predictive Computational Phenotyping; <sup>4</sup>Department of Biomolecular Chemistry; <sup>5</sup>McArdle Laboratory for Cancer Research; <sup>6</sup>Department of Biostatistics and Medical Informatics; University of Wisconsin-Madison, Madison, WI  
<sup>7</sup>Morgridge Institute for Research, Madison, WI





## Introduction & Motivation

- Problem:** Given a chemical **compound** and **target** protein, determine whether the compound **binds** with the target.
- Experimental tests in a small molecule screening facility are expensive.

**Virtual Screening (VS)** can help accelerate drug discovery by **proposing the most probable** compounds for experimental testing.

## Two Main VS Strategies

- Structure-Based:** docking methods that requires target structure info.
- Ligand-Based:** *similar* compounds bind similarly. No structure knowledge of target required.




## Case Study: SSB-PriA

- Keck lab screened 75000 compounds to see which disrupt the SSB-PriA interaction. (**known**)
- Untested library of 25000 new compounds. (**unknown**)

**Goal:** Assess **quality of MTNN and other common methods** on this unknown set. We are only given one chance. Also gives us a chance to assess **quality of evaluation metrics** as they translate to real world value.

**Real-World Impact:** Help screening facilities by proposing top 250 most likely compounds. Perfect ranking not important.


## Single Task vs. Multi-Task Neural Networks



## Project Pipeline

- Stage 1: Hyperparameter Selection Stage, prune hyperparameter space
- Stage 2: Cross Validation Stage, select best model based on early enrichment
- Stage 3: Prospective Screening Stage, evaluate best models with new experiments

## Cross Validation




## Prospective Screening

### Hits in Top 250 Predictions

Number of active compounds in top 250 predictions from seven selected models and a chemical similarity baseline compared to the number of experimentally-identified actives.

Model	Actives	Actives not in baseline	SIM clusters	MCS clusters
Experimental	62	--	32	37
Similarity Baseline	31	--	14	8
Consensus Docking	0	0	0	0
STNN-C	23	4	12	7
STNN-R	29	13	16	11
MTNN-C	30	6	15	9
LSTM	1	1	1	1
Random Forest	40	10	16	9
IRV	29	5	13	7



An UpSet plot showing the overlap between the selected models and the chemical similarity baseline on PriA-SSB prospective. The plot generalizes a Venn diagram by indicating the overlapping sets with dots on the bottom and the size of the overlaps with the bar graph.

## High-throughput Computing



## Future Work

- Test ensembles that combine classification and regression models
- Scale to more diverse chemical libraries with millions of untested chemicals
- Assess alternative chemical feature representations

## References

- Scigenis. "Schematic illustration of docking a small molecule ligand (green) to a protein target (black) forming a protein-ligand complex." [en.wikipedia.org/wiki/Docking\\_\(molecular\)](https://en.wikipedia.org/wiki/Docking_(molecular))
- S. Lusher and G. Schaftenaar. "2-D searching Tutorial" <http://www.cmbi.ru.nl/edu/bioinf4/2D-Prac/2d.shtm>
- GitHub repository [https://github.com/gitter-lab/pria\\_lifechem](https://github.com/gitter-lab/pria_lifechem)